Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
Top Cited Papers
- 1 February 2010
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 62 (2), 205-217
- https://doi.org/10.1016/j.jaad.2009.06.050
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Quality of life impairment in hidradenitis suppurativa: A study of 61 casesJournal of the American Academy of Dermatology, 2007
- Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patientsJournal of the American Academy of Dermatology, 2007
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Medical treatment of hidradenitis suppurativaExpert Opinion on Pharmacotherapy, 2004
- A Review of the Use of Infliximab to Manage Cutaneous DermatosesJournal of Cutaneous Medicine and Surgery, 2004
- Infliximab for the treatment of hidradenitis suppurativaJournal of the American Academy of Dermatology, 2003
- Hidradenitis suppurativa associated with Crohn?s disease and spondyloarthropathy: response to anti-TNF therapyThe Esophagus, 2003
- Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesionsBritish Journal of Dermatology, 1996
- The prevalence of hidradenitis suppurativa and its potential precursor lesionsJournal of the American Academy of Dermatology, 1996
- Mediation of hidradenitis suppurativa by androgens.BMJ, 1986